miR-25-3p表达水平与急慢性肝衰竭预后的关系探讨-东南大学学报医学版

miR-25-3p表达水平与急慢性肝衰竭预后的关系探讨

单位：广安市人民医院肝胆外科, 四川广安 638001

分类号：R575.3

出版年·卷·期（页码）：2021·40·第六期（766-771）

摘要：

目的: 探讨微小核糖核酸-25-3p(miR-25-3p)表达水平与急慢性肝衰竭预后的关系。方法: 纳入我院2018年9月至2020年9月收治的急慢性肝衰竭患者84例为肝衰竭组, 分别取同期收治的慢性乙肝(CHB)患者77例及同期体检者66例作为CHB组、对照组。比较3组血清miR-25-3p及总胆红素(TBIL)、白蛋白(ALB)、天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、乙肝病毒基因(HBV-DNA)水平。分析肝衰竭组miR-25-3p表达与肝功能、HBV-DNA的相关性以及预后危险因素, 绘制受试者工作特征(ROC)曲线分析miR-25-3p评估肝衰竭组预后的曲线下面积(AUC)。结果: 肝衰竭组和CHB组血清TBIL、AST、ALT水平高于对照组, miR-25-3p、ALB水平低于对照组; 肝衰竭组血清miR-25-3p表达水平低于CHB组, TBIL、AST、ALT水平高于CHB组, 差异均有统计学意义(P < 0.05)。肝衰竭组患者血清miR-25-3p表达与TBIL、AST、ALT呈负相关(P < 0.05)。在84例急慢性肝衰竭患者中, 3个月内生存55例, 死亡29例。死亡组血清miR-25-3p表达水平低于生存组, TBIL、AST、ALT水平高于生存组, 差异均有统计学意义(P < 0.05)。Cox分析显示血清miR-25-3p表达水平增高对急慢性肝衰竭预后有保护作用, TBIL、AST、ALT增高是预后危险因素(P < 0.05)。血清miR-25-3p评估急慢性肝衰竭预后的AUC为0.768。结论: 急慢性肝衰竭患者血清miR-25-3p表达水平明显下降, 其高表达可能有利于降低死亡率。

Objective: To investigate the relationship between the expression of microrna-25-3p (miR-25-3p) and the prognosis of acute and chronic liver failure.Methods: 84 patients with acute and chronic liver failure admitted to our hospital from September 2018 to September 2020 were selected as liver failure group, 77 cases of chronic hepatitis B (CHB) and 66 cases of physical examination in the same period were selected as CHB group and control group. The levels of serum miR-25-3p and total bilirubin (TBIL), albumin (ALB), aspartate aminotransferase (AST), alanine aminotransferase (ALT) and hepatitis B virus-DNA (HBV-DNA) were compared among the three groups. The correlation between miR-25-3p expression and liver function, HBV-DNA and prognostic risk factors in liver failure group were analyzed. The receiver operating characteristic(ROC) curve was drown to analyze the area under the curve (AUC) of miR-25-3p in evaluating the prognosis of liver failure group.Results: Serum TBIL, AST, ALT in liver failure group and CHB group were higher than those of control group, serum miR-25-3p and ALB were lower than control group; serum miR-25-3p in liver failure group was lower than CHB group, serum TBIL, AST, ALT was higher than CHB group (P < 0.05). Serum miR-25-3p was negatively correlated with TBIL, AST, and ALT in liver failure group (P < 0.05). Among 84 patients with acute and chronic liver failure, 55 survived and 29 died within 3 months, respectively. The serum miR-25-3p in the death group was lower than that in the survival group, and the serum TBIL, AST, and ALT were higher than those in the survival group (P < 0.05). COX analysis suggested that increased serum miR-25-3p had a protective effect on the prognosis of acute and chronic liver failure, and increased TBIL, AST and ALT were prognostic risk factors (P < 0.05).Conclusion: Serum miR-25-3p is significantly decreased in patients with acute and chronic liver failure, and its high expression may be beneficial to reduce mortality.

参考文献：

[1] KUMAR R, MEHTA G, JALAN R. Acute-on-chronic liver failure[J]. Clin Med, 2020, 20(5): 501-504.
[2] 章益民, 谢中阳, 李兰娟. 肝衰竭诊治进展与热点问题[J]. 中国临床医生杂志, 2020, 48(11): 5-9.
[3] YANG L, WU T, LI J, et al. Bacterial infections in acute-on-chronic liver failure[J]. Semin Liver Dis, 2018, 38(2): 121-133.
[4] TAO Y C, WANG M L, WANG M, et al. Quantification of circulating miR-125b-5p predicts survival in chronic hepatitis B patients with acute-on-chronic liver failure[J]. Digest Liver Dis, 2019, 51(3): 412-418.
[5] FISHER L. Retraction: exosomal miR-25-3p derived from hypoxia tumor mediates IL-6 secretion and stimulates cell viability and migration in breast cancer[J]. RSC Adv, 2021, 11(11): 6257.
[6] 华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 中华临床感染病杂志, 2018, 11(6): 401-410.
[7] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960.
[8] ZHAO R H, SHI Y, ZHAO H, et al. Acute-on-chronic liver failure in chronic hepatitis B: an update[J]. Expert Rev Gastroent, 2018, 12(4): 341-350.
[9] PU C, JIANG C, LANG L, et al. Combination of microRNAs and cytokines: a method for better evaluation of acute-on-chronic liver failure[J]. Clin Lab, 2018, 64(3): 247-256.
[10] SANCHEZ-MEJIAS A, KWON J, CHEW X H, et al. A novel SOCS5/miR-18/miR-25 axis promotes tumorigenesis in liver cancer[J]. Int J Cancer, 2018, 144(2): 311-321.
[11] 薛亚军, 杜雅彦, 周奕君, 等. MiR-25-3p靶向NOTCH1对食管鳞癌细胞ECA109侵袭, 迁移, 增殖的影响[J]. 安徽医科大学学报, 2020, 55(1): 75-80.
[12] 程燕, 何启胜. 血清miR-451a、miR-25-3p、GAS8-AS1联合检测用于早期甲状腺乳头状癌的诊断[J]. 国际内分泌代谢杂志, 2020, 40(5): 300-303.
[13] ZHOU D X, DONG L, YANG L S, et al. Identification and analysis of circRNA-miRNA-mRNA regulatory network in hepatocellular carcinoma[J]. IET Syst Biol, 2020, 14(6): 391-398.
[14] LU G, CHENG Z, WANG S, et al. Knockdown of long non-coding RNA SNHG14 protects H9c2 cells against hypoxia-induced injury by modulating miR-25-3p/KLF4 axis in vitro[J]. J Cardiovasc Pharm, 2020, 77(3): 334-342.
[15] 辛敏, 曹竹君, 谢青. 免疫功能紊乱在慢加急性肝衰竭发生, 发展中的作用及研究进展[J]. 肝脏, 2019, 24(12): 142-144.
[16] 高梦丹, 覃岭, 孙坚萍, 等. HBV相关慢加急性肝衰竭患者外周血CD3⁺CD56⁺自然杀伤T淋巴细胞中TIM-3的表达及意义[J]. 临床肝胆病杂志, 2019, 35(9): 2006-2010.
[17] 杨正弦, 潘乐涵, 龚建平. 急性肝衰竭的病因及治疗进展[J]. 国际外科学杂志, 2020, 47(10): 710-716.
[18] 高飞, 张卫青, 梁首勤, 等. 血清白蛋白、前白蛋白和转铁蛋白在评价慢性肝衰竭患者营养支持中的应用[J]. 实用医学杂志, 2017, 33(4): 603-605.
[19] 罗杰, 杜展, 汤仕龙, 等. HBV相关慢加急性肝衰竭患者血清miRNA表达谱及临床预测价值[J]. 检验医学与临床, 2017, 14(2): 190-192.
[20] GENZ B, COLEMAN M A, IRVINE K M, et al. Overexpression of miRNA-25-3p inhibits Notch1 signaling and TGF-β-induced collagen expression in hepatic stellate cells[J]. Sci REP-UK, 2019, 9(1): 1-17.
[21] 蔡莉, 孙力, 胡菊萍. miR-25-3p通过靶向TLR4抑制糖尿病肾病炎症反应[J]. 中国免疫学杂志, 2020, 36(20): 25-29.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录